非小细胞肺癌脑转移的靶向和免疫治疗
脑转移是非小细胞肺癌（non-small cell lung cancer,NSCLC）常见并发症,发生率为30%-50%,大大影响了患者的生存质量。NSCLC一旦发生脑转移预后极差,未经治疗者的中位生存期仅为1个月-2个月。基于肺癌驱动基因的靶向治疗为肺癌脑转移提供了新的方法。目前免疫治疗已成为肿瘤治疗的新方向,它能通过刺激机体免疫系统提高抗肿瘤免疫效应。临床上靶向治疗和免疫治疗的结合运用可使患者获益。...
Saved in:
| Published in: | 中国肺癌杂志 Vol. 19; no. 8; pp. 530 - 532 |
|---|---|
| Main Author: | |
| Format: | Journal Article |
| Language: | Chinese |
| Published: |
解放军总医院肿瘤内一科, 北京,100853
2016
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | 脑转移是非小细胞肺癌（non-small cell lung cancer,NSCLC）常见并发症,发生率为30%-50%,大大影响了患者的生存质量。NSCLC一旦发生脑转移预后极差,未经治疗者的中位生存期仅为1个月-2个月。基于肺癌驱动基因的靶向治疗为肺癌脑转移提供了新的方法。目前免疫治疗已成为肿瘤治疗的新方向,它能通过刺激机体免疫系统提高抗肿瘤免疫效应。临床上靶向治疗和免疫治疗的结合运用可使患者获益。 |
|---|---|
| Bibliography: | Lung neoplasms; Brain metastasis; Immunotherapy; Targeted therapy Brain metastasis, a common complication of non-small cell lung cancer（NSCLC） with an incidence rate of 30%-50%, significantly affects the patients＇ quality of life. The prognosis of patients of NSCLC with brain metastasis is extremely poor, the average median survival is only 1 m-2 m without treatment. The targeted therapy based on lung cancer driven gene is a new treatment. Besides, the immunotherapy which can enhance the effect of anti-cancer by simulating the immune system is a new approach. The combination of targeted therapy and immunotherapy can greatly benefit patients in clinical work. Qi SONG,Shunchang JIAO,Fang LI（Oncology Department, General Hospital of PLA, Beijing 100853, China） 12-1395/R |
| ISSN: | 1009-3419 1999-6187 |
| DOI: | 10.3779/j.issn.1009-3419.2016.08.08 |